Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML0173

Sigma-Aldrich

Reversan

≥98% (HPLC)

Sinónimos:

CBLC4H10, N-[3-(4-Morpholinyl)propyl]-5,7-diphenyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C26H27N5O2
Número de CAS:
313397-13-6
Peso molecular:
441.52
MDL number:
MFCD01528184
UNSPSC Code:
12161501
PubChem Substance ID:
329825203
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

faintly yellow to yellow

solubility

DMSO: ≥8 mg/mL at ~60 °C

storage temp.

2-8°C

SMILES string

O=C(NCCCN1CCOCC1)c2cnn3c(cc(nc23)-c4ccccc4)-c5ccccc5

InChI

1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32)

InChI key

JTRXWCLQFAZHGP-UHFFFAOYSA-N

Application

Reversan may be used in cell signaling studies.

Biochem/physiol Actions

Nontoxic MRP1 function inhibitor; MRP1 and Pgp function inhibitor; multidrug transporter inhibitor
Reversan increases the efficacy of vincristine and etoposide and increases the sensitivity of murine models of neuroblastoma to conventional chemotherapy.
Reversan is a selective and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp) inhibitor.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
101M4615V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Catherine A Burkhart et al.
Cancer research, 69(16), 6573-6580 (2009-08-06)
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine
Michelle J Henderson et al.
Journal of the National Cancer Institute, 103(16), 1236-1251 (2011-07-30)
Although the prognostic value of the ATP-binding cassette, subfamily C (ABCC) transporters in childhood neuroblastoma is usually attributed to their role in cytotoxic drug efflux, certain observations have suggested that these multidrug transporters might contribute to the malignant phenotype independent
Katharina Esser-Nobis et al.
Hepatology (Baltimore, Md.), 62(2), 397-408 (2015-04-14)
Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper
Frank Loganzo et al.
Molecular cancer therapeutics, 14(4), 952-963 (2015-02-04)
Antibody-drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico